Nuvilex Highlights The Technology And Advances Behind The Cutting-Edge Cell-in-a-Box® Technology Platform

Nuvilex, Inc. (OTCQB: NVLX), an emerging biotechnology provider of cell and gene therapy solutions through its ongoing acquisition of the assets of SG Austria, today discussed the proprietary Cell-in-a-Box® technology, providing additional information about the science and technology behind the product.

Creation of Cell-in-a-Box® was a technological concept over 20 years ago, originally designed for studying potential ways to create protection for cells and destruction of viruses through neutralizing antibody production. This concept soon became a reality and developed over time to have a wide variety of uses, some of which are still being realized. In the past decade, this concept has advanced to the point we can now fully address the enormous humanitarian value and applications as well as substantial clinical potential for treatment of an extremely diverse set of diseases.

The founding principle was to develop an artificial, semi-permeable capsule with sufficient permeability that oxygen and nutrients could reach encapsulated cells while cellular products could be released into the bloodstream or adjacent tissues. In addition, the capsule material had to remain robust, yet restrictive enough to exclude antibodies and immune cells. Otherwise, antibodies or immune cells would cause or allow recognition of the foreign capsule material, or the cells inside, and ultimately cause rejection and destruction of the live cellular implant.

After substantial research, initial capsules were created which offered strength and durability. The SG Austria Cell-in-a-Box® patented encapsulation platform uses natural cotton, or cellulose sulphate, as the building blocks for the capsule itself, ultimately providing an optimum permeability balance. One of the best and most exciting properties was that the resulting capsules were non-allergenic. Additional intervening years included advances in purification, manufacturing, and chemistry of the cellulose sulphate to enable careful manipulation of the materials to allow specific size and characteristic capsules to be made.

Over time, advances in material science made it possible to vary the capsule size giving rise to a range from ~0.7 to 1.4 cm in diameter, about the size of the head of a pin. Further refinement has produced an extremely robust, yet flexible material. This capability enables varying numbers of cells to be placed inside each capsule, anywhere from a few cells to 10,000 or more cells. Even specific pore sizes can be created for the capsule based on the application. This unusual feature therefore provides an ability to limit or regulate what components or constituents can enter and exit the capsules.

During the past several months together SG Austria and Nuvilex have been provided an opportunity to make new advances in the encapsulation material, production and resulting capsules, some of which will be destined for use in future company activities. Thus, the encapsulation technology platform and its resulting capsule can thus be viewed as a robust, implantable device which provides strength, support, protection and durability for live cells inside yet flexible enough to allow transplantation into animals and humans without giving rise to an immune response and therefore they alleviate the need for immunosuppression.

Dr. Robert Ryan, Chief Executive Officer of Nuvilex, commented, “Together with SG Austria, we are working to commercialize the Cell-in-a-Box ® technology platform through co-development activities and by establishing out-licensing deals with other companies that have potentially useful therapeutic cell systems that they would like to encapsulate and implant. Given the unique and advantageous properties of the Cell-in-a-Box ® technology, we anticipate seeing it incorporated into the cutting edge of medical treatments across a broad swath of unmet medical needs.”

About Nuvilex

Nuvilex, Inc. (OTCQB: NVLX) is an emerging international biotechnology provider of live, clinically useful, encapsulated cells and services for the research and medical communities. Through substantial effort, all aspects of our corporate activities alone and in concert with SG Austria are moving toward completion and a strong future together. Our company’s planned clinical offerings will include cancer, diabetes and other treatments using the company’s industry-leading cell and gene therapy expertise and cutting edge, live-cell encapsulation.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving risks and uncertainties including product demand, market competition, and Nuvilex’s ability to meet current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Copyright Business Wire 2010